Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. (Q52958869)
Jump to navigation
Jump to search
scientific article published on 21 January 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. |
scientific article published on 21 January 2015 |
Statements
Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. (English)
Julia Åivo
Merja Soilu-Hänninen
21 January 2015
280
12-15